ATE205494T1 - Pyridylfuran- und pyridylthiphenderivate und deren pharmazeutische verwendung - Google Patents

Pyridylfuran- und pyridylthiphenderivate und deren pharmazeutische verwendung

Info

Publication number
ATE205494T1
ATE205494T1 AT97310375T AT97310375T ATE205494T1 AT E205494 T1 ATE205494 T1 AT E205494T1 AT 97310375 T AT97310375 T AT 97310375T AT 97310375 T AT97310375 T AT 97310375T AT E205494 T1 ATE205494 T1 AT E205494T1
Authority
AT
Austria
Prior art keywords
pyridylfuran
pyridylthiphene
derivatives
pharmaceutical use
compounds
Prior art date
Application number
AT97310375T
Other languages
English (en)
Inventor
Akiyoshi Kawai
Makoto Kawai
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE205494T1 publication Critical patent/ATE205494T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT97310375T 1997-01-06 1997-12-19 Pyridylfuran- und pyridylthiphenderivate und deren pharmazeutische verwendung ATE205494T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IBPCT/IB97/00002 1997-01-06

Publications (1)

Publication Number Publication Date
ATE205494T1 true ATE205494T1 (de) 2001-09-15

Family

ID=11004514

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97310375T ATE205494T1 (de) 1997-01-06 1997-12-19 Pyridylfuran- und pyridylthiphenderivate und deren pharmazeutische verwendung

Country Status (11)

Country Link
US (3) US6048880A (de)
EP (1) EP0853083B1 (de)
JP (1) JP3384962B2 (de)
AT (1) ATE205494T1 (de)
BR (1) BR9800228A (de)
CA (1) CA2226039C (de)
DE (1) DE69706642T2 (de)
DK (1) DK0853083T3 (de)
ES (1) ES2161418T3 (de)
GR (1) GR3037073T3 (de)
PT (1) PT853083E (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT853083E (pt) * 1997-01-06 2001-12-28 Pfizer Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica
JP3409029B2 (ja) * 1997-10-03 2003-05-19 メルク フロスト カナダ アンド カンパニー Ｐｄｅｉｖ阻害剤としてのアリールチオフェン誘導体
WO1999064425A1 (en) * 1998-06-09 1999-12-16 Neurogen Corporation Substituted thienocycloalkylpyrazoles: dopamine receptor subtype specific ligands
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
US7088987B1 (en) * 2000-07-07 2006-08-08 Bellsouth Intellectual Property Corporation Pre-paid wireless interactive voice response system with variable announcements
EP1186605B1 (de) * 2000-09-07 2003-04-16 Chisso Corporation Organische Elektrolumineszenzanordung mit einem Dipyridylthiophenderivat
JP2004523476A (ja) * 2000-10-12 2004-08-05 スミスクライン・ビーチャム・コーポレイション ＮＦ−κＢ阻害剤
JP4212470B2 (ja) 2001-06-26 2009-01-21 アムジェン フレモント インク． Ｏｐｇｌへの抗体
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
EP1432703A1 (de) * 2001-09-05 2004-06-30 Smithkline Beecham Plc Heterocycle-carboxamide derivate als raf kinase inhibitoren
US7105513B2 (en) * 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
EP1394159A1 (de) * 2002-08-13 2004-03-03 Warner-Lambert Company LLC Neue Thiophen-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
TWI271402B (en) * 2002-10-15 2007-01-21 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
US7196106B2 (en) * 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
CA2511823A1 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
SE0300091D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
US20080275066A1 (en) * 2004-07-02 2008-11-06 Novo Nordisk A/S Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists
RU2448104C2 (ru) * 2005-12-19 2012-04-20 Зингента Лимитед Замещенные ароматические гетероциклические соединения, как фунгициды
TWI394749B (zh) 2006-03-27 2013-05-01 內維亞諾醫學公司 具有激酶抑制劑活性之雜戊環
CA2690141A1 (en) * 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
CA2727928A1 (en) * 2008-06-18 2009-12-23 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
JP2011527680A (ja) * 2008-07-09 2011-11-04 メルク・シャープ・エンド・ドーム・コーポレイション Ｊａｎｕｓキナーゼの阻害剤
CN102395585A (zh) 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8586624B2 (en) 2009-12-16 2013-11-19 N30 Pharmaceuticals, Inc. Thiophene inhibitors of S-nitrosoglutathione reductase
EP2420495A1 (de) * 2010-07-29 2012-02-22 Institut Pasteur Neuartige Derivate, die als antivirale Mittel von Nutzen sind
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021696A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP2013533318A (ja) * 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリールおよびその使用
PE20141044A1 (es) 2010-10-13 2014-09-07 Millennium Pharm Inc Heteroarilos y sus usos
KR20140024377A (ko) * 2011-04-15 2014-02-28 조지아 테크 리서치 코포레이션 나프탈렌 디이미드의 스탄닐 유도체와 관련 조성물 및 방법
JP5989229B2 (ja) * 2012-04-20 2016-09-07 アッヴィ・インコーポレイテッド イソインドロン誘導体
AU2013270036B2 (en) 2012-05-31 2016-12-01 Phenex Pharmaceuticals Ag Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR(gamma)
FR2993563B1 (fr) * 2012-07-20 2015-12-18 Metabrain Res Derives de thiophenes utiles dans le traitement du diabete
CN108069949A (zh) * 2017-12-22 2018-05-25 佛山汉方中医医院有限公司 烷基取代的哌嗪甲基噻吩二环腈类化合物、制备方法及其用途
CN107936002A (zh) * 2017-12-22 2018-04-20 佛山汉方中医医院有限公司 一种异丙基哌嗪胺基噻吩二环腈类化合物及其用途
CN108003148A (zh) * 2017-12-22 2018-05-08 佛山汉方中医医院有限公司 异丙基哌嗪噻吩二环腈类化合物、制备方法及其用途
CN108069948A (zh) * 2017-12-22 2018-05-25 佛山汉方中医医院有限公司 一种ssao抑制剂、其制备方法及其用途
CN108069947A (zh) * 2017-12-22 2018-05-25 佛山汉方中医医院有限公司 含二甲胺噻吩和异丙基哌嗪胺基结构的二环腈类化合物及用途
CN108084171A (zh) * 2017-12-22 2018-05-29 佛山汉方中医医院有限公司 哌嗪噻吩二环腈类化合物、制备方法及其用途
CN108084169A (zh) * 2017-12-22 2018-05-29 佛山汉方中医医院有限公司 一种硝基噻吩的二环腈类化合物及其用途
CN108069950A (zh) * 2017-12-22 2018-05-25 佛山汉方中医医院有限公司 一种含噻吩的二环腈类ssao抑制剂、制备方法及其用途
GEP20247585B (en) 2019-12-19 2024-01-25 Bayer Ag Furoindazole derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8905526D0 (en) 1989-03-10 1989-04-19 Fujisawa Pharmaceutical Co N-containing heterocyclic compounds,processes for the preparation thereof and composition comprising the same
JPH03232884A (ja) 1990-02-07 1991-10-16 Kumiai Chem Ind Co Ltd チオフェン誘導体及びこれを含む除草剤
WO1998002430A1 (en) * 1996-07-11 1998-01-22 Pfizer Pharmaceuticals Inc. Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
PT853083E (pt) * 1997-01-06 2001-12-28 Pfizer Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica

Also Published As

Publication number Publication date
CA2226039A1 (en) 1998-07-06
JP3384962B2 (ja) 2003-03-10
US20040142976A1 (en) 2004-07-22
EP0853083B1 (de) 2001-09-12
DK0853083T3 (da) 2001-11-19
DE69706642D1 (de) 2001-10-18
EP0853083A1 (de) 1998-07-15
JPH10195070A (ja) 1998-07-28
ES2161418T3 (es) 2001-12-01
DE69706642T2 (de) 2002-02-07
GR3037073T3 (en) 2002-01-31
BR9800228A (pt) 1999-09-08
US6048880A (en) 2000-04-11
PT853083E (pt) 2001-12-28
US6696470B2 (en) 2004-02-24
US20020022729A1 (en) 2002-02-21
CA2226039C (en) 2004-12-28

Similar Documents

Publication Publication Date Title
DE69706642D1 (de) Pyridylfuran- und Pyridylthiphenderivate und deren pharmazeutische Verwendung
PT1404347E (pt) Nucleosidos 4'-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c
NO992524L (no) Konsenserte bicykliske pyrimidin-derivater
AP9701041A0 (en) Pyridylpyrrole compounds.
SE9902987D0 (sv) Novel compounds
EE200100558A (et) Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
BR9507917A (pt) Reagente para preparar um agente radiofarmacêutico agente formador de imagem processo para preparar o mesmo kit para preparar uma preparação farmacêutica uso do reagente agente radioterapêutico composição e agente radiofarmacêutico
SE9903544D0 (sv) Novel compounds
BR0008840A (pt) Derivados de camptotecina tendo atividade antitumoral
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
BR9909474A (pt) Formas ii, cristalina e v de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, solvato de etanol de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, composição, composto, uso de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, e, processos para o tratamento de uma infecção viral em um humano e para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol
BR0315580A (pt) Derivados de metileno uréia
DE60001586D1 (de) Diphenyl-piperidin derivate
PT992509E (pt) Novos derivados macrolidos
ATE389655T1 (de) Pyrimidinderivate
IT1256320B (it) Derivati eterociclici
IT1276162B1 (it) Geranilgeranil-derivati,procedimento per la loro preparazione e relative composizioni farmaceutiche
BRPI0207102A8 (pt) forma cristalina, composição farmacêutica, e, uso de uma forma cristalina.
EE200200143A (et) 4-bensüülaminokinoliini konjugaadid sapphappega ja nende heteroanaloogid, nende valmistamismeetod ning neid ühendeid sisaldavad ravimid ja nende kasutamine
AP9801235A0 (en) Erythromycin derivatives.
YU25202A (sh) Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera
DE69904025T2 (de) Kondensierte Pyrimidinderivate und diese enthaltende pharmazeutische Zubereitungen
CA2392902A1 (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation
PT952157E (pt) Derivados 9a, 11b-desidro de 9-oxima-3-ceto-6-o-metileritromicina
BR0214644A (pt) Uso de derivados de ácido 4-oxobutanóico no tratamento de inflamação

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee